Shield Therapeutics PLC | Mutual Funds
Mutual Funds that own Shield Therapeutics PLC
JPMorgan Funds - Global Healthcare Fund
5,212,346
4.48%
-750,000
0.07%
05/31/2018
Marlborough UK Micro Cap Growth Fund
2,955,587
2.54%
56,903
0.08%
03/29/2018
BlackRock Strategic Fds. - European Opportunities Ext. Fund
2,665,270
2.29%
-31,396
0.08%
11/30/2017
City Financial - UK Opportunities Fund
740,218
0.64%
-15,500
0.19%
02/28/2018
Fidelity Institutional Funds - UK Fund
216,158
0.19%
-72,707
0.02%
03/31/2018
Aviva Investors - European Equity Fund
0
0%
-183,373
0%
06/30/2018
| Address |
Northern Design Centre
Gatehead Quays GH NE8 3DF
United Kingdom
|
|
Employees
|
- |
| Website |
http://shieldtherapeutics.com |
| Updated |
07/08/2019 |
| Shield Therapeutics Plc is a pharmaceutical company. It engages in the development and commercialization of secondary care focused pharmaceuticals. Its products include Feraccru, which treats oral problems with iron deficiency anaemia; and PT20, which treats hyperphosphatemia. |
